Department Of Pediatric Oncology
Investigator
Nobuko Hijiya, MD
Phone
212-305-9770
Email
nh2636@cumc.columbia.edu

My expertise is in pediatric hematology and oncology, with a particular focus on leukemias and lymphomas, or cancers of the blood, bone marrow, or lymph nodes. I am especially interested in chronic myeloid leukemia (CML). Because children are growing and developing, CML treatment and management present unique challenges—the same treatment options that work best for grown-ups may not be the right strategies for kids.

I treat children, adolescents, and young adults. I love working with this population and developing long-lasting relationships with my young patients. I am especially passionate about delivering personalized care to each of them—because no two kids are the same. Diseases like leukemia and lymphoma are challenging for anyone, but they can be especially hard on children. Symptoms like fatigue and joint pain can make it hard to move, play, and act like a kid, and some treatments can have severe side effects. I work to manage children’s symptoms and choose the right treatments for their disease, based on their individual needs. Helping these children is the most satisfying goal I can imagine.

My research revolves around the treatment of pediatric leukemias and lymphomas. I continue to explore the impact of current treatments, and I collaborate with basic science researchers to translate their breakthroughs into new drug development. I have also been involved in cancer survivorship research. As a professor and the section head of pediatric oncology, I am deeply committed to educating and mentoring medical students, residents, and fellows and helping to prepare the next generation of leaders in pediatric hematology/oncology.


Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A Study for Children with Acute Lymphoblastic Leukemia Using Study Drug Carfilzomib
Cancer A Study for Patients with Advanced Melanoma, Solid Tumors or Lymphoma Using Study Drug Pembrolizumab
Pediatric Solid Tumors [ CLOSED ] Study of Selinexor in Pediatric Solid Tumors, including CNS Tumors
Pediatric Solid Tumors [ CLOSED ] Testing combination drugs in children with solid tumors that have come back or are resistant to current anti-cancer therapy
Cancer [ CLOSED ] Study of Combination Therapies in Children with Relapsed Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkins Lymphoma (NHL)
Cancer [ CLOSED ] Study of Drug Injection with Chemotherapy in Children, Adolescents, and Young Adults with Relapse of Actue Lymphoblastic Leukemia
Lymphoma [ CLOSED ] Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma (Ages 1-30)
Leukemia [ CLOSED ] Study of Nivolumab in Combination with 5-Azacytidine in Acute Myeloid Leukemia (AML) - Children and Adults Age 1 to 30
Childhood Leukemia [ CLOSED ] Study of Nivolumab in Combination with 5-Azacytidine in Acute Myeloid Leukemia (AML) - Children and Adults Age 1 to 30
Cancer Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Childhood Leukemia [ CLOSED ] Decitabine and Vorinostat Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) in Children & Young Adults with Acute Myeloid Leukemia
Lymphoma Study of Relatlimab and Nivolumab in Patients Under 30 Years Old with Classical Hodgkin Lymphoma (cHL) and Non-Hodgkin Lymphoma (NHL)
Cancer Study of Relatlimab and Nivolumab in Patients Under 30 Years Old with Classical Hodgkin Lymphoma (cHL) and Non-Hodgkin Lymphoma (NHL)
Childhood Leukemia PEPN2113: Study of Uproleselan in Children with AML, MDS, or MPAL